Barclays’s ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) ECTE Stock Holding History

Barclays’s Portfolio ECTE Stock Details ECTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-10,000	Closed	-$30K	–	7954
2014 Q1	$30K	Sell	10,000 -2,646	-21%	-$8.72K	﹤0.01%	6382
2013 Q4	$38K	Buy	12,646 +2,646	+26%	+$7.38K	﹤0.01%	6379
2013 Q3	$20K	Buy	+10,000	New	+$27.1K	﹤0.01%	6540

Other funds holding ECTE

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

NPC

National Planning Corporation El Segundo, California $726K AUM 14.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's ECTE Position: Q2 2014 in Review

Barclays sold out of ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) (ECTE) in Q2 2014, closing a stake of 10,000 shares — an estimated $30K sold.

Barclays first reported a position in ECTE in Q3 2013 and held it in 3 quarters. The position peaked at $38K in Q4 2013. 25 funds tracked by Wall St. Rank hold ECTE as of Q2 2014.

Barclays reported no remaining ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position as of Q2 2014 after selling out during the quarter.
Barclays sold 10,000 ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) shares in Q2 2014, an estimated $30K.
Barclays first reported a position in ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) in Q3 2013 and held it in 3 quarters.
Barclays's ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) position peaked at $38K in Q4 2013.
25 funds tracked by Wall St. Rank held ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE) as of Q2 2014.

Based on Barclays's 13F filing for Q2 2014, filed 14 Aug 2014.